Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort
Journal of Gastroenterology and Hepatology · 2026
DOI: 10.1111/jgh.70358 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Thananya Jinato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Cirrhosis, Liver Neoplasms, Gastrointestinal Microbiome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Second Century Fund, Ratchadapiseksompotch Fund, Faculty of Medicine Chulalongkorn University, Thailand Science research and Innovation Fund Chulalongkorn University.
Abstract (Originalsprache)
Background
Gut microbiota, microbial metabolites, and inflammatory cytokines play key roles in the pathogenesis of cirrhosis and hepatocellular carcinoma (HCC); however, data from Southeast Asia are limited. This study examined microbial composition, intestinal permeability, butyrate‐related gene expression, and cytokine profiles in Thai patients with cirrhosis, with and without HCC.
Methods
This cross‐sectional study included 30 healthy controls, 33 patients with cirrhosis without HCC, and 44 patients with HCC (HCC–cirr). Fecal samples were analyzed using 16S rRNA sequencing. Microbial functional profiles were predicted using KEGG Orthology–based pathway inference. Gut permeability markers (intestinal fatty acid–binding protein [I‐FABP] and lipopolysaccharide‐binding protein [LBP]), butyrate‐associated gene (BCoAT) expression, and cytokine profiles were assessed.
Results
Alpha diversity (Chao1) was significantly lower in HCC–cirr patients than in healthy controls ( p < 0.001) and patients with cirrhosis ( p = 0.008). Beta diversity also differed significantly between HCC–cirr and controls ( p = 0.008). Ligilactobacillus , Catenibacterium , and Alloprevotella were enriched in the cirrhosis group, whereas HCC–cirr patients showed increased Ruminococcus gnavus and reduced butyrate producers ( Coprococcus , Subdoligranulum ). Functional prediction suggested pathway differences between cirrhosis and HCC–cirr, including folate, sulfur, tyrosine metabolism, and steroid biosynthesis. BCoAT expression was significantly decreased in HCC ( p = 0.006). Plasma LBP and I‐FABP were significantly elevated in HCC–cirr ( p = 0.033, p < 0.001), with I‐FABP also higher than in cirrhosis ( p = 0.002). Proinflammatory cytokines (GM‐CSF, IL‐10, IL‐18, IL‐1α, IL‐7, IL‐8, and M‐CSF) were elevated in HCC–cirr.
Conclusions
Among the Thai cohort, HCC with cirrhosis was associated with distinct gut microbial changes, reduced BCoAT expression, increased gut permeability, and cytokine alterations, highlighting the contribution of gut dysbiosis and microbial by‐products to liver disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Center of Excellence in Kidney-Liver-Microbiota, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
- Microbiome Analysis Center, George Mason University, Manassas, Virginia, USA.
- Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, Virginia, USA.
ORCID-Profile: Jasmohan S Bajaj, Natthaya Chuaypen
Förderung
- Second Century Fund
- Ratchadapiseksompotch Fund, Faculty of Medicine Chulalongkorn University
- Thailand Science research and Innovation Fund Chulalongkorn University
- Fundamental Fund 2025
- Program Management Unit for Human Resources & Institutional Development, Research and Innovation
Zitieren
APA
Jinato, T., Sikaroodia, M., Gilleveta, P. M., Dissayabutra, T., Tangkijvanich, P., Bajaj, J. S., & Chuaypen, N. (2026). Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70358
Vancouver
Jinato T, Sikaroodia M, Gilleveta PM, Dissayabutra T, Tangkijvanich P, Bajaj JS, et al. Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70358
BibTeX
@article{Jinato2026,
author = {Jinato, Thananya and Sikaroodia, Masoumeh and Gilleveta, Patrick M and Dissayabutra, Thasinas and Tangkijvanich, Pisit and Bajaj, Jasmohan S and Chuaypen, Natthaya},
title = {Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70358}
}
EUVIMED